On April 15, 2026, Acurx Pharmaceuticals, Inc. announced a registered direct offering to sell 816,068 shares of common stock at $3.03 each, alongside pre-funded warrants, aiming to raise approximately $2.5 million for working capital. The closing is expected on April 16, 2026, with restrictions on further share issuance for 15 days post-offering.